Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: Results of a randomized, placebo-controlled clinical trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 3, 2016, Pages 246-253

  Gandhi, Rajesh T ^a,b   Kwon, Douglas S ^a,b   Macklin, Eric A ^a   Shopis, Janet R ^a   McLean, Anna P ^b   McBrine, Nicole ^b   Flynn, Theresa ^a   Peter, Lauren ^f   Sbrolla, Amy ^a   Kaufmann, Daniel E ^b,c   Porichis, Filippos ^b   Walker, Bruce D ^a,b,d   Bhardwaj, Nina ^e   Barouch, Dan H ^b,f   Kavanagh, Daniel G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HIV 1; Immunization; mRNA transfected dendritic cell; Randomized controlled trial; Therapeutic vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MESSENGER RNA; NEF PROTEIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VACCINATION; GENETICS; HIV INFECTIONS; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; AIDS VACCINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HUMANS; IMMUNIZATION; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, MESSENGER; TRANSFECTION;

EID: 84959121365     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000852     Document Type: Article

References (34)

1. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251-263.
2. Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465-472.
3. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 1997; 186:1177-1182.
4. Weissman D, Ni H, Scales D, et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol. 2000;165:4710-4717.
5. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98:49-56.
6. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods. 2002;259:191-203.
7. Garcia F, Plana M, Climent N, et al. Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother. 2013;9: 2445-2452.
8. Walsh SR, Bhardwaj N, Gandhil RT. Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. Curr HIV Res. 2003;1:205-216.
9. Su Z, Vieweg J, Weizer AZ, et al. Enhanced induction of telomerasespecific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 2002;62:5041-5048.
10. Granelli-Piperno A, Golebiowska A, Trumpfheller C, et al. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci U S A. 2004;101:7669-7674.
11. de Arruda LB, Chikhlikar PR, August JT, et al. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology. 2004;112:126-133.
12. Marsh M, Thali M. HIV's great escape. Nat Med. 2003;9:1262-1263.
13. Marques ET Jr, Chikhlikar P, de Arruda LB, et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem. 2003;278:37926-37936.
14. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
15. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
16. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000;181:121-131.
17. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97:3382-3387.
18. Lichterfeld M, Kaufmann DE, Yu XG, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004; 200:701-712.
19. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-Tlymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol. 2004; 78:2187-2200.
20. Nguyen KL, llano M, Akari H, et al. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology. 2004;319:163-175.
21. Kofman A, Graf M, Deml L, et al. Codon usage-mediated inhibition of HIV-1 gag expression in mammalian cells occurs independently of translation. Tsitologiia. 2003;45:94-100.
22. Allard SD, De Keersmaecker B, de Goede AL, et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol. 2012;142:252-268.
23. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46-53.
24. O'Neill DW, Bhardwaj N. Differentiation of peripheral blood monocytes into dendritic cells. In: Coligan JE, et al, eds. Current Protocols in Immunology; 2005. Chapter 22: Unit 22F 24.
25. Kavanagh DG, Kaufmann DE, Sunderji S, et al. Expansion of HIVspecific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm-or lysosome-targeted Nef. Blood. 2006;107: 1963-1969.
26. Liang KY, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Indian J Stat Ser B. 2000;62: 134-148.
27. Ndhlovu ZM, Proudfoot J, Cesa K, et al. Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol. 2012;86: 6959-6969.
28. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev. 2013;254:170-189.
29. Miller EA, Spadaccia MR, O'Brien MP, et al. Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr. 2012;61: 535-544.
30. Miller E, Bhardwaj N. Advances in dendritic cell immunotherapies for HIV-1 infection. Expert Opin Biol Ther. 2014;14:1545-1549.
31. Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol. 2010; 134:140-147.
32. Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV. Available at: http://ir.argostherapeutics.com/releasedetail.cfm? ReleaseID=890486.
33. Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013;5:166ra162.
34. Anguille S, Smits EL, Lion E, et al. Clinical use of dendritic cells for cancer therapy. The Lancet Oncology. 2014;15:e257-e267.